ArticleMicrobial cell factories2026
Harnessing the endophytic Clavispora lusitaniae for the biogenic synthesis of ethylene glycol-capped cerium oxide nanoparticles: a green approach to combat respiratory Pseudomonas aeruginosa.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe utilization of endophytes as specialized microbial cell factories offers a sustainable and high-efficiency platform for the biosynthesis of functionalized nanomaterials. This study investigates the potential of a novel endophytic yeast, Clavispora lusitaniae, to produce cerium oxide nanoparticles (CeO₂NPs) and evaluates their efficacy against extensively drug-resistant (XDR) P. aeruginosa.
resultsAn endophytic yeast, C. lusitaniae, was isolated for the first time from the medicinal plant Artemisia judaica and employed for the biosynthesis of CeO₂NPs, followed by surface capping with ethylene glycol (EG) to modify the nanoparticle surface properties. The synthesized nanoparticles were characterized using UV-Vis, FTIR, XRD, TEM, and DLS. These analyses confirmed the formation of spherical EG-CeO₂NPs with an average size of 8-20 nm. EG-CeO₂NPs exhibited strong antibacterial activity against XDR P. aeruginosa strains, with a minimum inhibitory concentration ranging from 0.6 to 1.25 mg/mL. Furthermore, these nanoparticles demonstrated potent anti-biofilm efficacy, achieving reductions of up to 89%. Mechanistic investigations demonstrated that EG-CeO₂NPs disrupt bacterial cell membranes, leading to intracellular protein leakage and elevated lipid peroxidation (indicated by increased malondialdehyde levels). Furthermore, the expression levels of quorum sensing (e.g., lasR and rhlR) and virulence-associated genes (e.g., toxA and exoS) were markedly downregulated by up to 87% compared to untreated controls.
conclusionsThis study establishes C. lusitaniae as a robust microbial cell factory for synthesizing functionalized CeO₂NPs with potent activity against XDR P. aeruginosa. Our results demonstrate the potential of microbial bioprocessing in engineering prospective nanotechnological platforms to combat antimicrobial resistance. However, further studies evaluating colloidal behavior under physiologically relevant conditions, mammalian-cell cytotoxicity, and in vivo efficacy are required before biomedical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.